|
|
Blood, Vol. 107, Issue 5, 1806-1809, March 1, 2006
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group
Blood Shimada et al.
107: 1806
Supplemental materials for: Shimada et al
Files in this Data Supplement:
- Table S1. Primers for KIT mutation analysis (PDF, 11.1 KB)
- Figure S1. A schema of AML99 protocol (PDF, 22.4 KB) -
FAB/M3 and Down syndrome patients were treated with the different protocol. Patients who were younger than 2 years old or initial WBC count <100,000/ml were treated with Induction A regimen [VP-16, CA and MIT, (ECM)]. Patients who were older than 2 years old and initial WBC count > 100,000/ml were treated with Induction B regimen [VP-16, CA and IDA, (ECI)]. If patients achieved complete remission (CR) after consecutive chemotherapy (HCEI or Induction C), patients were categorized into three risk group (low, intermediate and high) according to the results of cytogenetic analyses. M1, M2 and M3 marrow represents blasts count are <5%, <25% and >25% of mononuclear cells in bone marrow.
- Figure S2. A schema of treatment protocol for t(8;21)-AML patients in AML99 (PDF, 22.2 KB) -
Patients received different induction therapy A or B according to age or initiail WBC count. If the initial WBC count was < 50,000/ml and patients were categorized into low risk group, they received with additional 5 consecutive chemotherapy (HCEI, mini-ECM, HDE, HCEI, HCE). If the initial WBC count was > 50,000/ml and patients were categorized into intermediate risk group, patients were encouraged to receive allo-SCT after 2 consecutive chemotherapy if the HLA-matched donor was available.
|
|
